Routes of infection and clinical outcome of Mexican women reactive to anti-hepatitis C virus antibodies

Hepatology Research

Volumn 36, Issue 2, 2006, Pages 100-106

  Chiquete, Erwin ^a,b   Sánchez, Laura V ^a,b   Panduro, Arturo ^a,b  

^a HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Cirrhosis; Hepatitis B; Hepatitis C; Liver; Serology; Test; Transfusion

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INTERFERON; VIRUS DNA; VIRUS RNA;

ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GYNECOLOGIC SURGERY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INFECTION RISK; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MEXICO; MIXED INFECTION; OBSTETRIC OPERATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION;

EID: 33749368713     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2006.06.012     Document Type: Article

References (40)

1. Vivas-Arceo C., Benavides S.A., De Jesus Trujillo J., Panduro A., and Rivas-Estilla A.M. Hepatitis C virus: prevalence and routes of infection among blood donors of West Mexico. Hepatol Res 25 (2003) 115-123
2. Kim Y.S., Ahn Y.O., and Lee H.S. Risk factors for hepatitis C virus infection among Koreans according to the hepatitis C virus genotype. J Korean Med Sci 17 (2002) 187-192
3. Sánchez J.L., Sjögren M.H., Callahan J.D., et al. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg 63 (2000) 242-248
4. Abdourakhmanov D.T., Hasaev A.S., Castro F.J., and Guardia J. Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan. Eur J Epidemiol 14 (1998) 549-553
5. Chiquete E., Sánchez L.V., Maldonado M., Quezada D., and Panduro A. Prediction of the hepatitis C viremia using immunoassay data and clinical expertise. Ann Hepatol 4 (2005) 107-114
6. de Torres M., and Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2 (2003) 5-11
7. Marcellin P., Asselah T., and Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 36 (2002) S47-S56
8. Flamm S.L., Parker R.A., and Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol 93 (1998) 597-600
9. Dubois F., Desenclos J.C., Mariotte N., Goudeau A., and The Collaborative Study Group. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 25 (1997) 1490-1496
10. Davoren A., Dillon A.D., Power J.P., et al. Outcome of an optional HCV screening program for blood transfusion recipients in Ireland. Transfusion 42 (2002) 1501-1506
11. Harris D.R., Gonin R., Alter H.J., et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 134 (2001) 120-124
12. Tong M.J., el-Farra N.S., Reikes A.R., and Co R.L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332 (1995) 1463-1466
13. Minola E., Prati D., Suter F., et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 99 (2002) 4588-4591
14. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M.E., and Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341 (1999) 22-26
15. Takaki A., Wiese M., Maertens G., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 (2000) 578-582
16. Méndez-Sánchez N., Aguilar-Ramírez J.R., Reyes A., et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 3 (2004) 30-33
17. Koerner K., Cardoso M., Dengler T., Kerowgan M., and Kubanek B. Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang 74 (1998) 213-216
18. Soza A., Arrese M., Gonzalez R., et al. Clinical and epidemiological features of 147 Chilean patients with chronic hepatitis C. Ann Hepatol 3 (2004) 146-151
19. Barrett S., Goh J., Coughlan B., et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 49 (2001) 423-430
20. Bakr I., Rekacewicz C., El Hosseiny M., et al. Higher clearance of HCV infection in females compared to males. Gut (2006) 24 January, [Epub ahead of print]
21. Marín-López A. Bancos de Sangre. Rev Gastroenterol Mex 67 (2002) S11-S12
22. Chiquete E., Sánchez L.V., Becerra G., Quintero A., Maldonado M., and Panduro A. Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican transfusion center. Ann Hepatol 4 (2005) 275-278
23. Sookoian S., and Castaño G. Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies. Ann Hepatol 4 (2002) 179-182
24. Dal Molin G., Tiribelli C., and Campello C. A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection. Ann Hepatol 2 (2003) 76-83
25. Kiely P., Kay D., Parker S., and Piscitelli L. The significance of third-generation HCV RIBA-indeterminate. RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays. Transfusion 44 (2004) 349-358
26. Lu S.N., Tung H.D., Chen T.M., et al. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion?. J Viral Hepat 11 (2004) 563-570
27. Rivas-Estilla A.M., Sánchez L.V., Matsui O., et al. Identification of hepatitis C virus (HCV) genotypes in infected patients from the west of Mexico. Hepatol Res 12 (1998) 121-130
28. Sánchez L.V., Maldonado M., Bastidas-Ramírez B.E., Norder H., and Panduro A. Genotypes and S-gene variability of Mexican hepatitis B virus strains. J Med Virol 68 (2002) 22-34
29. Zhang J., and Yu K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280 (1998) 1690-1691
30. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
31. Dore G.J., Law M., MacDonald M., and Kaldor J.M. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 26 (2003) 171-184
32. Chlabicz S., Bonifatiuk I., and Radziwon P. Prevalence of hepatitis C virus antibodies among blood donors in north-eastern Poland. Hepatol Res 33 (2005) 206-210
33. Semmo N., Barnes E., Taylor C., et al. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 365 (2005) 327-329
34. Uto H., Hayashi K., Kusumoto K., et al. Spontaneous elimination of hepatitis C virus RNA in individuals with persistent infection in a hyperendemic area of Japan. Hepatol Res 34 (2005) 28-34
35. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 40 (2002) 4068-4071
36. Georgiadou S.P., Zachou K., Rigopoulou E., et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 11 (2004) 358-365
37. Raimondo G., Cacciamo G., and Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease?. Ann Hepatol 4 (2005) 100-106
38. Koike K., and Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res 34 (2006) 65-73
39. Zeuzem S., and Herrmann E. Dynamics of hepatitis C virus infection. Ann Hepatol 1 (2002) 56-63
40. Saito T., Watanabe H., Shao L., et al. Transmission of hepatitis C virus quasispecies between human adults. Hepatol Res 30 (2004) 57-62